ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

BMJ Supportive & Palliative Care is a leading academic journal dedicated to advancing the field of supportive and palliative care, published by the esteemed BMJ PUBLISHING GROUP in the United Kingdom. With an ISSN of 2045-435X and an E-ISSN of 2045-4368, this journal showcases high-quality, peer-reviewed articles that cater to a diverse audience, including healthcare professionals, researchers, and students. Notably, it holds a commendable impact factor, reflecting its credibility and influence within the academic community. As of 2023, the journal ranks in the top quartile (Q1) for Medical and Surgical Nursing and holds prestigious positions in the Q2 category for Medicine (miscellaneous) and Oncology (nursing), demonstrating its significance in multiple disciplines. Research published in this journal aims to enhance patient-centered care practices and improve health outcomes, making it an invaluable resource for innovative studies and discussions in the field. With a commitment to open access principles, BMJ Supportive & Palliative Care serves as a pivotal platform for disseminating knowledge and supporting the ongoing professional development of its readership.

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Neuro-Oncology Advances, published by Oxford University Press, is an esteemed open-access journal dedicated to advancing the field of neuro-oncology. Established in 2019, the journal has quickly gained recognition for its commitment to disseminating high-quality research, evidenced by its impressive Q1 rankings in Neurology (Clinical), Oncology, and Surgery categories as of 2023. With a rigorous peer-review process and a focus on innovative findings, Neuro-Oncology Advances serves as a vital platform for researchers, practitioners, and students seeking to stay at the forefront of developments in the diagnosis and treatment of nervous system tumors. The journal is accessible globally, ensuring that critical knowledge is available to help improve clinical outcomes and foster collaboration within this crucial interdisciplinary field.

Welcome to NEUROREHABILITATION, a premier journal dedicated to advancing the field of rehabilitation, specializing in neurology and physical therapy. Published by IOS PRESS, the journal has established itself as a crucial platform for disseminating high-quality, peer-reviewed research since its inception in 1991. Located in the Netherlands, NEUROREHABILITATION has achieved significant recognition within the academic community, reflected in its impressive impact factor and Scopus rankings, including a Q2 categorization in Rehabilitation and Physical Therapy, highlighting its relevance and influence in these essential domains. With a commitment to enhancing clinical practices and outcomes for individuals with neurological conditions, this journal serves as an invaluable resource for researchers, clinicians, and students alike. Although it currently operates under a subscription model, NEUROREHABILITATION continues to contribute meaningfully to the ongoing dialogue in rehabilitation sciences, making it a key player in shaping the future of therapy and patient care.

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

Ophthalmology Glaucoma is a premier academic journal dedicated to advancing the understanding and management of glaucoma, a leading cause of irreversible blindness worldwide. Published by Elsevier, this journal covers a broad spectrum of topics within the field of ophthalmology, providing a platform for groundbreaking research and clinical insights. With an impressive impact factor that places it in the Q1 category of ophthalmology journals, and a commendable Scopus ranking of 29 out of 137, Ophthalmology Glaucoma is recognized for its rigorous peer-review process and high-quality publications. Since its inception in 2018, the journal has focused on disseminating innovative findings and treatment modalities to enhance patient care and outcomes. Researchers, clinicians, and students are encouraged to explore the Open Access options available, promoting wider accessibility to critical scientific knowledge. By staying at the forefront of ophthalmic research, Ophthalmology Glaucoma plays an essential role in shaping practices and policies that improve eye health globally.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.